Cargando…

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

SIMPLE SUMMARY: This study aimed to determine the optimal maintenance therapy and selection criteria for patients with platinum-sensitive recurrent ovarian cancer (PSROC). The study collected retrospective data from 51 patients with PSROC and found that olaparib (Ola) was superior to bevacizumab (Be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakanishi, Kazuho, Toyoshima, Masafumi, Ueno, Yuta, Suzuki, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216615/ https://www.ncbi.nlm.nih.gov/pubmed/37345206 http://dx.doi.org/10.3390/cancers15102869

Ejemplares similares

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Zinc deficiency is associated with gynecologic cancer recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Bartoletti, Michele, et al.
Publicado: (2020)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
por: Shaw, Heather M, et al.
Publicado: (2013)

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
por: Majić, Ana, et al.
Publicado: (2020)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
por: Zamorano, Abigail S., et al.
Publicado: (2017)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
por: Ma, Jiao, et al.
Publicado: (2019)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
por: Nagao, Shoji, et al.
Publicado: (2020)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_12htvumjqvvgvc1rahgfl1cn13